公司概况 » 咨询委员会
Jon Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He joined BioCryst as President and CEO in January 2007. The transformation that has taken place since then has advanced BioCryst to a company with its first product revenue and approvals, pivotal clinical programs and a diverse clinical pipeline, as well as the financial flexibility to build an enduring, successful biopharmaceutical company. Before joining BioCryst, he served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company, which culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe.